首页> 美国卫生研究院文献>British Journal of Cancer >Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil cisplatin epidoxorubicin 6S-leucovorin glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
【2h】

Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil cisplatin epidoxorubicin 6S-leucovorin glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

机译:使用5-氟尿嘧啶顺铂表阿霉素6S-亚叶酸钙谷胱甘肽和非格司亭进行每周一次的局部晚期胃癌密集化疗:意大利消化道癌研究小组(GISCAD)的一份报告。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Local extension prevents curative resection in more than two-thirds of gastric cancer patients. Unfortunately, resectability is one of the main prognostic factors in these patients, and survival is longer when tumours are completely removed. Preoperative chemotherapy is an attractive concept for obtaining curative resection. Thirty-two locally advanced unresectable gastric cancer patients were enrolled in five Italian Group for the Study of Digestive Tract Cancer (GISCAD) centres. For 16 patients, surgical unresectability was based on computerized tomography scan evaluation of tumour size (four patients) and invasion of adjacent structures (12 patients), whereas in another 16 patients locally advanced disease was confirmed by laparotomy. They received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S-stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 g m(-2). From the day after to the day before each chemotherapy administration, filgrastim was administered by subcutaneous injection at a dose of 5 microg kg(-1). One cycle of therapy consisted of eight weekly treatments. Fifteen of 32 patients (47%) responded to chemotherapy, whereas 13 (41 %) had stable disease and four (12%) progressed on therapy. Of the 15 responding patients, 13 were completely resected after chemotherapy and two of them had a complete pathological response. Two clinically responding patients were found unresectable at operation because of peritoneal seeding. At a median follow-up from the start of treatment of 24 months (range 11-39 months), 10 of 13 resected patients are alive and eight are relapse free. Three patients died after 11, 12, and 14 months respectively. Toxicity was acceptable: side-effects consisted mainly of grade II National Cancer Institute common toxicity criteria (NCICTC) leucopenia and thrombocytopenia in ten patients. Neither treatment-related death nor surgical complications in patients undergoing surgery were observed. This weekly intensive regimen enabled resection in half of previously inoperable tumours with a moderate toxicity. It can be offered to patients with locally advanced unresectable gastric cancer to obtain curative resection.
机译:局部扩展可防止超过三分之二的胃癌患者进行根治性切除。不幸的是,可切除性是这些患者的主要预后因素之一,并且当肿瘤被完全切除时生存期更长。术前化疗是获得根治性切除术的一个有吸引力的概念。在五个意大利消化道癌症研究中心(GISCAD)中心招募了32名本地晚期无法切除的胃癌患者。对于16例患者,手术切除性是基于计算机X线断层扫描评估肿瘤大小(4例)和侵犯邻近结构(12例),而在另外16例患者中,剖腹术证实了局部晚期疾病。他们每周接受顺铂40 mg m(-2),5-氟尿嘧啶500 mg m(-2),表柔比霉素35 mg m(-2),亚叶酸钙6立体异构体250 mg m(-2)和谷胱甘肽1.5 gm的给药。 (-2)。从每次化疗开始的第二天到第二天,通过皮下注射以5微克kg(-1)的剂量给予非格司亭。一个治疗周期包括每周八次治疗。 32例患者中有15例(47%)对化疗有反应,而13例(41%)病情稳定,4例(12%)治疗进展。在15例有反应的患者中,有13例在化疗后完全切除,其中2例具有完全的病理反应。由于腹膜播种,发现两名临床反应良好的患者无法手术切除。从治疗开始24个月(11-39个月)的中位随访期间,在13例切除的患者中,有10例活着,有8例无复发。三名患者分别在11、12和14个月后死亡。毒性是可以接受的:副作用主要由10名患者的II级国家癌症研究所共同毒性标准(NCICTC)白细胞减少症和血小板减少症组成。手术患者均未观察到与治疗相关的死亡或手术并发症。每周一次的强化治疗可以切除一半以前无法手术的肿瘤,并具有中等毒性。它可以提供给局部晚期无法切除的胃癌患者以进行根治性切除。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号